Cargando…

Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety

BACKGROUND: The increasing prevalence of carbapenem-resistant Gram-negative bacteria (CR-GNB) represents a global healthcare crisis. This study explored the efficacy and safety of Polymyxin B (PMB)-based regimens and factors influencing their effectiveness. METHODS: Patients with CR-GNB infections t...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Jian, Qi, Ting-Ting, Qu, Qiang, Long, Wen-Ming, Chen, Ying, Luo, Yue, Wang, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957303/
https://www.ncbi.nlm.nih.gov/pubmed/35345474
http://dx.doi.org/10.2147/IDR.S357746
_version_ 1784676737836122112
author Qu, Jian
Qi, Ting-Ting
Qu, Qiang
Long, Wen-Ming
Chen, Ying
Luo, Yue
Wang, Ying
author_facet Qu, Jian
Qi, Ting-Ting
Qu, Qiang
Long, Wen-Ming
Chen, Ying
Luo, Yue
Wang, Ying
author_sort Qu, Jian
collection PubMed
description BACKGROUND: The increasing prevalence of carbapenem-resistant Gram-negative bacteria (CR-GNB) represents a global healthcare crisis. This study explored the efficacy and safety of Polymyxin B (PMB)-based regimens and factors influencing their effectiveness. METHODS: Patients with CR-GNB infections treated with PMB for more than three days were enrolled in this retrospective study from 1st June 2018 to 30th April 2020. Data were collected on patient characteristics, bacterial culture, and drug-sensitivity test results; anti-infection treatment regimens, particularly details of PMB use; and adverse drug reactions. Clinical and microbiological efficacy, mortality, and safety of PMB-based regimens in CR-GNB infected patients were evaluated. Univariate analysis and multivariate logistic regression analyses were used to assess factors influencing efficacy and mortality. RESULTS: A total of 373 CR-GNB strains were cultured from 268 patients. About 41.04% of patients used PMB loading dose of 1.01 (0.84–1.69) mg/kg. Maintenance dose was 0.85 (0.82–1.00) mg/kg q12h. The clinical efficacy rate was 36.57% (98/268), the total bacterial clearance rate of PMB was 39.42%, and the all-cause mortality rate was 33.96%. The adverse drug reaction rate was 19.58%, among which the incidence of renal toxicity was highest (8.21%). Multivariate logistic regression analysis showed that clinical efficacy, bacterial clearance rate, and all-cause mortality were associated with patient-related facts, including mechanical ventilation use, underlying diseases (such as respiratory disease), the type and site of CR-GNB infection, and PMB administration timing and loading dose. CONCLUSION: PMB is a relatively safe and effective antibiotic drug for treatment of critically ill patients with CR-GNB infection; however, PMB use should be subject to guidelines recommendations for early administration, loading administration, and adequate administration, which could help to improve the clinical efficacy, microbiological efficacy, and mortality.
format Online
Article
Text
id pubmed-8957303
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-89573032022-03-27 Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety Qu, Jian Qi, Ting-Ting Qu, Qiang Long, Wen-Ming Chen, Ying Luo, Yue Wang, Ying Infect Drug Resist Original Research BACKGROUND: The increasing prevalence of carbapenem-resistant Gram-negative bacteria (CR-GNB) represents a global healthcare crisis. This study explored the efficacy and safety of Polymyxin B (PMB)-based regimens and factors influencing their effectiveness. METHODS: Patients with CR-GNB infections treated with PMB for more than three days were enrolled in this retrospective study from 1st June 2018 to 30th April 2020. Data were collected on patient characteristics, bacterial culture, and drug-sensitivity test results; anti-infection treatment regimens, particularly details of PMB use; and adverse drug reactions. Clinical and microbiological efficacy, mortality, and safety of PMB-based regimens in CR-GNB infected patients were evaluated. Univariate analysis and multivariate logistic regression analyses were used to assess factors influencing efficacy and mortality. RESULTS: A total of 373 CR-GNB strains were cultured from 268 patients. About 41.04% of patients used PMB loading dose of 1.01 (0.84–1.69) mg/kg. Maintenance dose was 0.85 (0.82–1.00) mg/kg q12h. The clinical efficacy rate was 36.57% (98/268), the total bacterial clearance rate of PMB was 39.42%, and the all-cause mortality rate was 33.96%. The adverse drug reaction rate was 19.58%, among which the incidence of renal toxicity was highest (8.21%). Multivariate logistic regression analysis showed that clinical efficacy, bacterial clearance rate, and all-cause mortality were associated with patient-related facts, including mechanical ventilation use, underlying diseases (such as respiratory disease), the type and site of CR-GNB infection, and PMB administration timing and loading dose. CONCLUSION: PMB is a relatively safe and effective antibiotic drug for treatment of critically ill patients with CR-GNB infection; however, PMB use should be subject to guidelines recommendations for early administration, loading administration, and adequate administration, which could help to improve the clinical efficacy, microbiological efficacy, and mortality. Dove 2022-03-22 /pmc/articles/PMC8957303/ /pubmed/35345474 http://dx.doi.org/10.2147/IDR.S357746 Text en © 2022 Qu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Qu, Jian
Qi, Ting-Ting
Qu, Qiang
Long, Wen-Ming
Chen, Ying
Luo, Yue
Wang, Ying
Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety
title Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety
title_full Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety
title_fullStr Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety
title_full_unstemmed Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety
title_short Polymyxin B-Based Regimens for Patients Infected with Carbapenem-Resistant Gram-Negative Bacteria: Clinical and Microbiological Efficacy, Mortality, and Safety
title_sort polymyxin b-based regimens for patients infected with carbapenem-resistant gram-negative bacteria: clinical and microbiological efficacy, mortality, and safety
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8957303/
https://www.ncbi.nlm.nih.gov/pubmed/35345474
http://dx.doi.org/10.2147/IDR.S357746
work_keys_str_mv AT qujian polymyxinbbasedregimensforpatientsinfectedwithcarbapenemresistantgramnegativebacteriaclinicalandmicrobiologicalefficacymortalityandsafety
AT qitingting polymyxinbbasedregimensforpatientsinfectedwithcarbapenemresistantgramnegativebacteriaclinicalandmicrobiologicalefficacymortalityandsafety
AT quqiang polymyxinbbasedregimensforpatientsinfectedwithcarbapenemresistantgramnegativebacteriaclinicalandmicrobiologicalefficacymortalityandsafety
AT longwenming polymyxinbbasedregimensforpatientsinfectedwithcarbapenemresistantgramnegativebacteriaclinicalandmicrobiologicalefficacymortalityandsafety
AT chenying polymyxinbbasedregimensforpatientsinfectedwithcarbapenemresistantgramnegativebacteriaclinicalandmicrobiologicalefficacymortalityandsafety
AT luoyue polymyxinbbasedregimensforpatientsinfectedwithcarbapenemresistantgramnegativebacteriaclinicalandmicrobiologicalefficacymortalityandsafety
AT wangying polymyxinbbasedregimensforpatientsinfectedwithcarbapenemresistantgramnegativebacteriaclinicalandmicrobiologicalefficacymortalityandsafety